Cancer clinical trials in the region Occitanie

344 currently recruiting clinical trials

Looking for clinical trials?

Clinical trial search is a complex process, with countless criteria to consider. Our AI assistant navigates this complexity with precise, expert-level analysis of the most relevant trials based on your medical profile. Our database is fully up to date, so you see only actively recruiting sites. It's fast and easy:

Create your account
Copy-paste your latest medical report
Our AI-based assistant does the rest for you

Whether you are a patient or a doctor, create an account to find and apply for the most relevant clinical trials:

Create your account

Phase 3 Prostate cancer #NCT06925737 #2024-517423-40-00

[IDeate-Prostate01] Étude clinique de l'IFINATAMAB DERUXTECAN chez les personnes atteintes d'un cancer de la prostate métastatique

Adenocarcinoma Metastatic Castration-resistant 1 2 Targeted therapy Hormone therapy

Systemic Treatment-Naive Chemotherapy

8 recruiting sites

Merck Sharp & Dohme LLC

Phase 3 Lung cancer #NCT06119581 #2023-503412-33-00

[SUNRAY-01]Etude sur le LY3537982 Plus l'immunothérapie avec ou sans chimiothérapie chez des participants atteints d'un cancer du poumon non à petites cellules muté KRAS G12C

NSCLC (Non-Small Cell Lung Cancer) Locally Advanced Metastatic KRAS G12C None Systemic Treatment-Naive

BRAF EGFR HER2 MET NTRK-1/2/3 RET ROS-1 Immunotherapy Chemotherapy Targeted therapy

18 recruiting sites

Eli Lilly et compagnie

Phase 3 Breast cancer #NCT06382948

[ADELA] ELACESTRANT + EVEROLIMUS chez les patients porteurs d'un cancer du sein avancé RH+/HER2-, ESR1 muté, progressant sous hormonothérapie et inhibiteurs de CDK4/6

HER2 Negative HR Positive Locally Advanced Metastatic ESR 1 2 Targeted therapy Hormone therapy

ESR Systemic Treatment-Naive Chemotherapy

8 recruiting sites

MedSIR

Phase 3 Lung cancer #NCT06881784 #2024-518154-16-00

[RASolve 301 ] Étude du DARAXONRASIB (RMC-6236) chez des patients atteints d'un CBNPC muté RAS ayant déjà été traités

NSCLC (Non-Small Cell Lung Cancer) Locally Advanced Metastatic Other KRAS HRAS KRAS G12C KRAS non G12C KRAS G12D NRAS 1 2 Immunotherapy Chemotherapy

Systemic Treatment-Naive

16 recruiting sites

Revolution Medicines, Inc.

Phase 3 Stomach and esophageal cancer #NCT06901531 #2024-519773-19-00

[LUCERNA] Étude du ZOLBETUXIMAB associé au PEMBROLIZUMAB et à la chimiothérapie chez les adultes atteints d'un cancer gastrique

Stomach Oesogastric junction Adenocarcinoma Locally Advanced Metastatic Claudin 18.2 None Systemic Treatment-Naive CPS Positive (1 <= X < 5) CPS Positive (5 <= X < 10) CPS Positive (X >= 10)

HER2 Immunotherapy Chemotherapy

18 recruiting sites

Astellas Pharma Développement mondial, Inc.

Phase 3 Colon cancer Rectal cancer #NCT06252649 #2022-502352-31-00

[CodeBreaK 301] Étude du SOTORASIB , du PANITUMUMAB et du FOLFIRI versus FOLFIRI avec ou sans BEVACIZUMAB chez des participants naïfs de traitement atteints d'un cancer colorectal métastatique avec mutation KRAS p.G12C

Adenocarcinoma Metastatic KRAS G12C None Systemic Treatment-Naive

Targeted therapy Targeted therapy

16 recruiting sites

Amgen

Phase 3 Breast cancer #NCT06790693 #2024-516162-11-00

[INAVO123] Étude évaluant l'efficacité et l'innocuité de l'INAVOLISIB associé à un inhibiteur CDK4/6 et au LETROZOLE par rapport à un placebo associé à un inhibiteur CDK4/6 et au LETROZOLE chez des participantes atteintes d'un cancer du sein avancé, PIK3CA muté, RH positif et à HER2 négatif

HER2 Negative HR Positive Locally Advanced Metastatic PIK3CA None Systemic Treatment-Naive

12 recruiting sites

Hoffmann-La Roche

Phase 3 Breast cancer #NCT06790693 #2024-516162-11-00

HER2 Negative HR Positive Locally Advanced Metastatic PIK3CA 1 Hormone therapy

Systemic Treatment-Naive Immunotherapy Chemotherapy Targeted therapy Car-T Bispecific T-cell engager antibodies Antibody Drug Conjugates (ADC)

12 recruiting sites

Hoffmann-La Roche

Phase 3 Acute leukemia #NCT05429632 #2024-512752-38-00

Mocravimod en traitement adjuvant et d'entretien chez les patients atteints de LAM et bénéficiant d'une allogreffe de cellules souches hématopoïétiques.

Acute myeloid leukemia (AML) None

8 recruiting sites

Priothera SAS

Phase 3 Acute leukemia #NCT06852222 #2024-520154-38-00

Étude du Bleximenib, du Venetoclax et de l'Azacitidine pour le traitement des participants atteints de leucémie myéloïde aiguë (LMA) nouvellement diagnostiquée

Acute myeloid leukemia (AML) None Treated / Controled KMT2A NPM1 None Systemic Treatment-Naive

13 recruiting sites

Janssen